Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: A 2-year randomized controlled clinical trial

Mayo Clinic Proceedings

Volumn 80, Issue 5, 2005, Pages 601-610

  Poland, Gregory A ^a   Jacobson, Robert M ^a   Koutsky, Laura A ^b   Tamms, Gretchen M ^c   Railkar, Radha ^c   Smith, Judith F ^c   Bryan, Janine T ^c   Cavanaugh Jr , Paul F ^c   Jansen, Kathrin U ^c,d   Barr, Eliav ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d VaxGen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; HUMAN PAPILLOMA VIRUS 16 VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONGENITAL DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG TOLERABILITY; FEMALE; GASTROENTERITIS; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INJECTION PAIN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NORMAL HUMAN; PNEUMONIA; PREGNANCY TERMINATION; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPONTANEOUS ABORTION; SUICIDE ATTEMPT; TRACHEOMALACIA; VACCINATION REACTION; VIRUS PARTICLE;

EID: 20944446494     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/80.5.601     Document Type: Article

References (30)

1. Cates W Jr, American Social Health Association Panel. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. Sex Transm Dis. 1999;26(4, suppl):S2-S7.
2. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-265.
3. Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence - implications for cervical disease progression and monitoring. J Med Virol. 2004;73:65-70.
4. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 1999;354:20-25.
5. Bosch FX, Manos MM, Munoz N, et al, International Biological Study on Cervical Cancer (IBSCC) Study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 1995;87:796-802.
6. Munoz N, Bosch FX, de Sanjose S, et al, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527.
7. Koutsky LA, Ault KA, Wheeler CM, et al, Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-1651.
8. Giuliano AR, Harris R, Sedjo RL, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. J Infect Dis. 2002;186:462-469.
9. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991;185:251-257.
10. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A. 1992;89:12180-12184.
11. Christensen ND, Cladel NM, Reed CA, et al. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology. 2001;291:324-334.
12. Giroglou T, Sapp M, Lane C, et al. Immunological analyses of human papillomavirus capsids. Vaccine. 2001;19:1783-1793.
13. Combita AL, Touze A, Bousarghin L, Christensen ND, Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol. 2002;76:6480-6486.
14. Evans TG, Bonnez W, Rose RC, et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis. 2001;183:1485-1493.
15. Palker TJ, Monteiro JM, Martin MM, et al. Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine. 2001;19:3733-3743.
16. McLaughlin-Drubin ME, Christensen ND, Meyers C. Propagation, infection, and neutralization of authentic HPV16 virus. Virology. 2004;322:213-219.
17. Brown DR, Fife KH, Wheeler CM, et al. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine. 2004;22:2936-2942.
18. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 2001;93:284-292.
19. Tobery TW, Smith JF, Kuklin N, et al. Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques. Vaccine. 2003;21:1539-1547.
20. Fife KH, Wheeler CM, Koutsky LA, et al. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine. 2004;22:2943-2952.
21. Lowe RS, Brown DR, Bryan JT, et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis. 1997;176:1141-1145.
22. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800-802.
23. Tukey JW, Ciminera JL, Heyse JF. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics. 1985;41:295-301.
24. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-226.
25. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003;97:1528-1540.
26. Hiatt RA, Kerner JF. Policies for implementing cervical cancer preventive and control strategies. In: Rohan TE, Shah KV, eds. Cervical Cancer: From Etiology to Prevention. Dordrecht, the Netherlands: Kluwer Academic Publishers; 2004:377-402.
27. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:37-48.
28. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290:781-789.
29. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604-615.
30. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97-107.